Axolotl Biosystems
Creates and engineers regenerative medicine and tissue engineering products and solutions, high-resolution desktop 3D bioprinters and bioinks capable of producing functional three dimensional living tissues.
- CEO / Founder
- Onur Samet Yildirim
- Team Size
- 2-10
- Stage
- Active
- Total Funding
- $20K
- Key Investors
- İTÜ Çekirdek
Technology & Products
Key Products
Axo A3 Bioprinting System; Axo A6 Bioprinting System; AxoMono Bioprinting System; Axo MEW Melt Electrowriting System; Axo Mechano Bioreactor; Axo Printheads; Bioinks
Technological Advantage
Proprietary multi-technology integration enables creation of complex tissue constructs with high resolution; desktop format reduces cost and footprint compared to traditional industrial bioprinters.
Differentiation
Value Proposition
Reduces high costs of traditional 3D bioprinting systems, provides accessibility to researchers and flexible open system architecture for construct design.
How They Differentiate
Offers multi-technology integration (melt electrowriting + extrusion) on a single desktop platform at lower cost than industrial competitors; open architecture provides flexibility for research customization.
Market & Competition
Target Customers
Bioengineering and tissue engineering research laboratories
Industry Verticals
Biotechnology; Medical Research; Tissue Engineering; Regenerative Medicine
Competitors
BICO; CELLINK; Aspect Biosystems; Regemat 3D; Allevi
Growth & Milestones
Growth Metrics
Turkish-based bioprinting company focused on regenerative medicine and tissue engineering products; 2-10 employees; Founded 2017
Major Milestones
Founded in 2016; Product launches including Axo A3, Axo A6, and AxoMono bioprinters; Participation in Formnext 2024
Notable Customers
Universities